HealthTech

Pharma distributors tighten the screws on e-pharmacies after PharmEasy debacle

Sowmya Ramasubramanian

Aparajita Saxena

August 01, 2023 | 7 Min Read

With PharmEasy set for a massive drop in valuation, pharma distributors are a wary lot. Having shared an uneasy relationship with e-pharmacies for the last five years, they’re changing the terms of their agreements with e-pharmacies to protect themselves from any further implosions in the space.

Being India's biggest e-pharmacy hasn’t been enough to keep the wolf from PharmEasy’s door.

Mired in losses—PharmEasy’s parent company recorded a loss of Rs 3,992 crore in the year ended March 2022—and burdened with debt, the company is currently attempting to orchestrate a life-saving rights issue to raise capital. This, however, would likely still see the valuation of Mumbai-headquartered PharmEasy drop from $5.5 billion during its last fundraise in 2021 to just north of $700 million, according to reports.

PharmEasy’s unravelling has cast a pall over the wider e-pharmacy space, with investors and industry experts wondering if this is just the start of a wider reckoning in the sector. Tata 1mg, PharmEasy’s biggest rival, also reported a loss of Rs 526 crore in the year ended March 2022.

Stakeholders in the pharma ecosystem are looking on with concern. Pharma distributors, spooked by the PharmEasy debacle, are reconsidering their already uneasy equation with e–pharmacies.

Corporate

Access unlimited content at a special discounted rate. Trusted by top VC’s and leading organizations, we provide bulk subscriptions for groups of 30+. Contact us for more details

Campus

Top educational institutions have collaborated with us for campus-wide subscriptions. For bulk campus-wide access, please get in touch.

Got a tip? If you have a lead we should be chasing at The CapTable, write to us at tips@the-captable.com

Join our community of 100,000+ top executives, VCs, entrepreneurs, and brightest student minds

Trusted by the best

Karthik Reddy

Blume Ventures

The CapTable brings a refreshing set of insights for us at the Blume team, highlighting stories that bring together the underlying business and founders with that of investors' journeys with these startups. It's an important perspective that very few bring to startup ecosystem enthusiasts.

Latest Articles

Inside streaming’s ad pivot: from viewers paying a fee to paying the price

Streaming promised freedom from cable. Instead, viewers are having to contend with ads, upsells, and data tracking, as the industry races to rebuild the exact model viewers paid to escape.

Anuj Suvarna

From Seed to Series A, founders are front-loading capital like never before

Early-stage founders are raising far larger seed and Series A rounds, accepting higher dilution to secure runway, talent, and execution speed, as India’s late-stage funding pipeline remains frozen for a third year.

Nikhil Patwardhan

The Byju’s money trail: How missing millions may have reached India from Singapore

Investigation of corporate filings reveals Byju Raveendran-controlled Singapore entities with no revenue or operations invested Rs 3,100 crore in Think & Learn, around the time disputed funds from the $533 million term loan allegedly reached the same offshore companies.

Pradip K Saha

Bad boy billionaires: India’s biggest fugitive economic offenders and here’s how much they owe to each bank

The CapTable looks at the fine print of the Lok Sabha data to identify who owes how much money to which bank.

Parvathi Benu

The regulator's gambit: Why SEBI took a stand against a business dynasty

SEBI's rare intervention, backing minority shareholders against the Jindal Poly Films family over alleged value transfers worth Rs 760 crore, could determine whether India's class-action framework becomes a real check on promoter power or remains ornamental.

Anuj Suvarna

Convinced that The Captable stories and insights
will give you the edge?

Convinced that The Captable stories
and insights will give you the edge?

Subscribe Now

Stories

Explore